Myeloid cells have long been noted to contribute to the formation of an immunosuppressive tumor promoting niche in the TME [44] and myeloid-specific PD-1 targeting could mediate myeloid cell–intrinsic effects that initiate systemic anti-tumor responses. This evidence concerns the gene PDCD1 and neoplasm.